HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 33-44

  Green, Andrew R ^a   Barros, Fabrício F T ^a   Abdel Fatah, Tarek M A ^b   Moseley, Paul ^b   Nolan, Christopher C ^a   Durham, Alice C ^a   Rakha, Emad A ^a,b   Chan, Stephen ^b   Ellis, Ian O ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast cancer; HER2 HER3 heterodimers; p21; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; HETERODIMER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIMERIZATION; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84900513002     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2925-7     Document Type: Article

References (55)

1. Yu DH, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19(53):6115-6121
2. Slamon DJ, Clark GM, Wong SG, Wendy J. Levin, Axel Ullrich WLM (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2lneu Oncogene. Science:177-183
3. Weinberg RA (2007) The biology of cancer. Garland Science
4. Witton CJ, Reeves JR, Going JJ, Timothy GC, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297. doi: 10.1002/path.1370
5. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5):361-370. doi: 10.1038/nrc1360
6. Vandergeer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal-transduction pathways. Annu Rev Cell Biol 10:251-337
7. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137
8. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, Ferguson KM (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25(17):7734-7742. doi: 10.1128/mcb.25.17.7734-7742.2005
9. Koninki K, Tanner M, Auvinen A, Isola J (2009) HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res. doi: 10.1186/bcr2322
10. Watanabe T, Fukutomi T, Tsuda H, Adachi I, Nanasawa T, Yamamoto H, Abe K (1993) Determination of c-Erbb-2 protein in prymary breast-cancer tissue-extract using an enzyme-immunoassay. Jpn J Cancer Res 84(12):1279-1286
11. Linggi B, Carpenter G (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16(12):649-656. doi: 10.1016/j.tcb.2006.10.008
12. Yen L, You XL, Al Moustafa AE, Batist Gerald, Nancy E, Hynes Sylvie Mader, Meloche S, Alaoui-Jamali MA (2000) Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19:3460-3469
13. Miaczynska M, Pelkmans L, Zerial M (2004) Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 16(4):400-406. doi: 10.1016/j.ceb.2004.06.005
14. Carpenter G (2003) ErbB-4: mechanism of action and biology. Exp Cell Res 284(1):66-77. doi: 10.1016/s0014-4827(02)00100-3
15. PinkasKramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15(10):2452-2467
16. Siegel PM, Ryan ED, Cardiff RD, Muller WJ (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18:2149-2164
17. Prigent SA, Gullick WJ (1994) Identification of c-erbb-3 binding-sites for phosphatidylinositol 3-kinase and SHC using an EGF receptor c-ERBB-3 chimera. EMBO J 13(12):2831-2841
18. Munster PN, Marchion DC, Basso AD, Rosen N (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3 '-kinase-AKT-dependent pathway. Cancer Res 62(11):3132-3137
19. Vogel CL, Cobleigh MA, Tripathy D, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
20. Burris H, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22(9):1621-1629. doi: 10.1200/jco.2004.08.065
21. Slamon DJ, Jones BL, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming TEW, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. New Engl J Med 344(11):783-792
22. Baselga J, Rischin D, Ranson M, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, S.D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
23. Nahta R, Esteva FJ (2006) Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8(6):1-8. doi: 10.1186/bcr1612
24. Romond EH, Perez EA, Bryant J, Suman VJ, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu SM, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann M. Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela M. Klein, James N. Ingle, and Norman Wolmark (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353(16):1673-1684
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-1672
26. Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, Rakha EA, Chan S, Ellis IO, Green AR (2014) Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Res Treat. doi: 10.1007/s10549-014-2871-4
27. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast-cancer.2. Histological type - relationship with survival in a large study with long-term follow-up. Histopathology 20(6):479-489
28. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
29. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219
30. Abd Dalia M, El-Rehim GB, Pinder Sarah E, Rakha Emad, Paish Claire, Robertson John FR, Macmillan Douglas, Blamey Roger W, Ellis Ian O (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 11:340-350. doi: 10.1002/ijc.21004
31. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Rwblamey J, Robertson FR, Nicholson R, Ellis I (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. British J Cancer 91:1532-1542. doi: 10.1038/sj.bjc.6602184
32. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AHS, Robertson JF, Blamey RW, Macmillan D, Ellis IO (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149-3156. doi: 10.1016/j.ejca.2006.08.015
33. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32. doi: 10.1002/cncr.22381
34. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet J-S, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302-2310. doi: 10.1158/1078-0432.ccr-08-2132
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi: 10.1007/s10549-006-9242-8
36. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: erbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933-8938. doi: 10.1073/pnas.1537685100
37. Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78(10):1385-1390. doi: 10.1038/bjc.1998.689
38. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97(4):453-457. doi: 10.1038/sj.bjc.6603910
39. Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE (2012) Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31(6):706-715. doi: 10.1038/onc.2011.275
40. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3-S8
41. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96(10):1504-1513. doi: 10.1038/sj.bjc.6603756
42. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) BCL-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth-factor receptor-negative tumors and in situ cancer. Br J Cancer 69(1):135-139. doi: 10.1038/bjc.1994.22
43. Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC (1994) Erbb3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth-factor. Mol Cell Biol 14(6):3550-3558
44. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2(77):ra31. doi: 10.1126/scisignal.2000352
45. Desbois-Mouthon C (2010) The HER3/ErbB3 receptor: a promising target in cancer drug therapy. Gastroenterol Clin Biol 34(4-5):255-259. doi: 10.1016/j.gcb.2010.03.002
46. Ku NO, Liao J, Omary MB (1997) Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272(52):33197-33203. doi: 10.1074/jbc.272.52.33197
47. Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138(6):1379-1394. doi: 10.1083/jcb.138.6.1379
48. Hattrup CL, Gendler SJ (2006) MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res 8(4):R37. doi: 10.1186/bcr1515
49. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochimica Et Biophysica Acta-Reviews on Cancer 1815(2):224-240. doi: 10.1016/j.bbcan.2011.01.001
50. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C (1995) Bidirectional interactions between the estrogen-receptor and the c-Erbb2 signalling pathways - heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63(4):560-567. doi: 10.1002/ijc.2910630417
51. Melanie Spears KJT, Munro Alison F, Cunningham Carrie A, Mallon Elizabeth A, Twelves Chris J, Cameron David A, Thomas Jeremy, Bartlett John MS (2011) In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1606-z
52. Dati C, Antoniotti S, Taverna D, Perroteau I, Debortoli M (1990) Inhibition of c-Erbb2 oncogene expression by estrogens in human breast-cancer cells. Oncogene 5(7):1001-1006
53. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Meijer L, Keyomarsi K, Hunt KK (2010) A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29(27):3896-3907. doi: 10.1038/onc.2010.151
54. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17(17):2235-2249. doi: 10.1038/sj.onc.1202132
55. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL (2003) Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 5(6):R242-R249. doi: 10.1186/bcr654